entertainment -WSS

entertainment

author：explore 2025-09-30 16:23:56 - browse：85

Photograph of a person wearing blue gloves counts money. -- health business coverage from STAT — Adobe

WASHINGTON — Doctors are staring down a cut to their Medicare pay next year, and while the news has united them in outrage, it’s also turned one specialty against another.

Medicare officials last week announced its major annual update to the way the program pays physicians. Along with other changes, it includes a policy that will boost payments to specialties that rely on evaluating and managing patients, as opposed to those that focus on procedures. But in Medicare, boosting payments in one area almost always means cutting them somewhere else. So to pay for that, doctors across the country will see a roughly 3% cut to a factor that determines how much Medicare pays them for caring for seniors.

The change has pitted certain specialties against primary care doctors. A host of surgeons’ groups, including the American College of Surgeons, plainly criticized family physicians in a recent letter to Medicare, saying there’s no “valid justification” for the boost and calling it an “inappropriate” overpayment.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Hospital chaplains balance Covid safety with patients’ spiritual needs

WSS

Obesity drug from Roche shows promise in early study

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Medicare Advantage overpayments discussion gets experts fired up

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

hotspot

entertainment

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

What a koala virus tells us about the human genome

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Profiling embryos to choose those with higher IQs is almost a reality

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Free medical tuition alone isn't enough to close gaps in primary care

Dobbs anniversary: the lost opportunity of abortion as health care

Cherokee Nation medical school graduates its first class

Malaria cases in Florida and Texas: Here’s what you need to know

HHS suspends federal funding for EcoHealth Alliance

explore

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Male doctors called my cancer incurable. A female doctor showed it wasn't

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

ALS treatment from Biogen, Ionis fails in study

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

In shift, Texas to cover initial consult for Afghan baby's gene therapy

hotspot

Wikipedia

entertainment

hotspot